Novo Nordisk A/S (NYSE:NVO) Stock Sold by Rep. Kevin Hern

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Novo Nordisk A/S (NYSE:NVO). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $1,001 and $15,000 in Novo Nordisk A/S stock on August 31st. The trade occurred in the Representative’s “KEVIN HERN TRADITIONAL IRA” account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026.
• Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026.
• Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
• Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026.

Novo Nordisk A/S Stock Down 1.0%

Shares of NVO traded down $0.40 during midday trading on Tuesday, reaching $38.31. 9,344,364 shares of the stock were exchanged, compared to its average volume of 17,108,484. The company has a market capitalization of $171.07 billion, a P/E ratio of 9.37, a PEG ratio of 1.27 and a beta of 0.74. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.55. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $64.16. The company’s 50 day moving average is $45.28 and its two-hundred day moving average is $43.86.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. The company had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 58.61%. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.54 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a dividend, which was paid on Tuesday, August 25th. Stockholders of record on Monday, August 17th were given a dividend of $0.5786 per share. This represents a dividend yield of 258.0%. The ex-dividend date of this dividend was Monday, August 17th. This is a negative change from Novo Nordisk A/S’s previous dividend of $1.2751. Novo Nordisk A/S’s dividend payout ratio is currently 20.05%.

Institutional Investors Weigh In On Novo Nordisk A/S

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. QRG Capital Management Inc. grew its holdings in Novo Nordisk A/S by 23.0% in the second quarter. QRG Capital Management Inc. now owns 175,187 shares of the company’s stock worth $8,398,000 after purchasing an additional 32,756 shares during the last quarter. Envestnet Portfolio Solutions Inc. boosted its position in shares of Novo Nordisk A/S by 9.8% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 16,205 shares of the company’s stock worth $777,000 after purchasing an additional 1,444 shares in the last quarter. Envestnet Asset Management Inc. boosted its position in shares of Novo Nordisk A/S by 1.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 4,031,114 shares of the company’s stock worth $193,250,000 after purchasing an additional 71,684 shares in the last quarter. State Street Corp grew its stake in Novo Nordisk A/S by 0.6% during the 2nd quarter. State Street Corp now owns 5,869,834 shares of the company’s stock worth $284,565,000 after buying an additional 32,641 shares during the last quarter. Finally, Wellington Altus USA Inc. acquired a new position in Novo Nordisk A/S during the 2nd quarter valued at about $115,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on NVO. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Berenberg Bank set a $47.00 price target on Novo Nordisk A/S in a report on Wednesday, August 12th. Finally, BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a research report on Tuesday. Three analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $64.94.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk entered an exclusive global license agreement with China’s Hengrui Pharma for HRS-1596, a phase 1-ready, once-weekly oral GLP-1/GIP drug for obesity and diabetes. The transaction includes $300 million upfront and could be worth up to $2.6 billion, plus royalties, giving Novo another potential oral treatment opportunity. China’s Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug
• Positive Sentiment: New CagriSema Phase 3 results showed 12.4% average weight loss after 60 weeks at a tested dose in adults with type 2 diabetes, strengthening Novo’s late-stage obesity pipeline and providing a competitive data point against Eli Lilly’s therapies. Novo Nordisk Just Beat Lilly in a Trial
• Positive Sentiment: Real-world analysis indicated that patients escalating Ozempic to 2 mg had a 6% lower risk of major cardiovascular events than patients switching to Mounjaro, supporting Ozempic’s clinical positioning, although the evidence is retrospective rather than from a randomized trial. Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly’s Mounjaro
• Positive Sentiment: Novo also continues its up-to-DKK 15 billion share-repurchase program, which may provide modest demand support and signal confidence in the company’s valuation. Novo Nordisk A/S share repurchase programme
• Negative Sentiment: Eli Lilly countered Novo’s Ozempic-related news by citing analyses suggesting its oral obesity drug Foundayo delivers greater weight loss and better blood-sugar control than higher-dose Ozempic, reinforcing competitive concerns. Lilly touts Foundayo advantage over Novo’s Ozempic pill
• Negative Sentiment: Analysts and investors remain concerned that Novo must develop a “second act” beyond its current GLP-1 franchise, particularly as Lilly expands its lead in parts of the obesity market. These concerns help explain why NVO has remained well below its prior peak despite the latest pipeline announcements.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Denmark-based global pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes injectable and oral medicines for diabetes, including insulin products and the GLP-1 therapies Ozempic and Rybelsus, as well as the obesity treatment Wegovy.

The company also develops and markets products for rare blood disorders, including hemophilia, along with growth hormone therapies and hormone replacement treatments.